According to the new market research report published by MarketsandMarkets, "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027", the global leukapheresis market is projected to reach USD 98 Million by 2027 from USD 65 Million in 2022, at a CAGR of 8.5%. The global leukopaks market is projected to reach USD 784 Million by 2027 from USD 146 Million in 2022, at a CAGR of 39.8%.
Key Market Players:
Key players in the leukapheresis industry include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).
Download PDF Brochure:
Leukapheresis Industry Dynamics
Drivers: Increasing number of blood donations
The global demand for blood and blood components is on the rise. According to the American Red Cross, approximately 21 million units of blood components are transfused every year in the US. The requirement for leukocytes/WBCs increases with the increase in demand for leukopaks in clinical research and the rising number of clinical trials for the development of CAR-T therapy for leukemia.
According to the WHO, in 2020, 79 countries worldwide have been collecting more than 90% of their blood supply from voluntary unpaid donors. This includes 60 self-sufficient countries that can completely meet the demand for donated blood from voluntary blood donations, including Iceland, Kenya, Nicaragua, Turkey, the UAE, and Zambia.
Restraints: Stringent donor recruitment criteria
To ensure the safety of blood donations for both donors and recipients, Red Cross societies across the globe have issued certain guidelines and eligibility requirements for blood donors, considering the ideal donor age, general health considerations, medical conditions, medical treatments, medications, vaccinations, as well as lifestyle and life events, in addition to choices such as tattoos and piercings.
However, the most important eligibility criterion for donating leukocytes is human leukocyte antigen typing. The human immune system uses these markers to distinguish between its own cells and foreign ones. As a result, HLA typing is typically performed during collection to ensure the specificity and easy identification of leukocytes.
Opportunities: Leukapheresis for pediatric patients
Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side effects and risks of conventional treatments such as chemotherapy for children.
Moreover, according to the American Cancer Society, leukemia is the most common cancer detected in children and adolescents in the US (28% and 13%, respectively). The most common leukemias in children are ALL and AML, with the latter being more effectively treated by leukapheresis. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market. However, therapeutic leukapheresis has been uncommonly performed, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed and emerging markets.
Request Sample Pages:
Challenges: Blood transfusion safety in developing countries
WBC transfusions have been associated with the risks of transmitting infectious agents such as HIV, HBV, HCV, and malaria. Infection through the blood supply is a major issue, especially in developing countries such as India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during WBC transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the globe; moreover, the necessity of this step is more pronounced in developing countries, where the burden of these diseases is higher. Even though authorities in various developing countries are currently ensuring blood testing, according to the WHO, only 57% of hospitals performing transfusions have systems to report adverse events, and only 50% of reporting hospitals have transfusion committees. Moreover, in countries with greater malaria transmission, more than 30% of the blood donors can carry malaria parasites, which can be transmitted by transfusion. Thus, ensuring blood safety is a major challenge faced by blood and blood component suppliers and healthcare institutions in developing countries.
Asia Pacific expected to grow at the highest CAGR during the forecast period
In 2021, North America accounted for the largest share of the leukapheresis products market. Factors like strong presence of a large number of players and a large number of ongoing CAR T-cell therapy clinical trials contribute to stronghold of this region.
Speak to Analyst:
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Comments